Cell-Based Immunoassays
Drug discovery is a multidisciplinary process aimed at identifying potential new medicines. It involves identifying screening hits, optimizing them through medicinal chemistry to enhance their properties, and validating targets for efficacy and safety. At TME Scientific, we offer comprehensive drug discovery services, including target identification and validation, lead identification and candidate optimization, and specialized cell model services. Explore our offerings to enhance and streamline your drug discovery journey.
Summary Table of Key In Vitro Assays for Immunotherapies:
Partner with TME Scientific for your in vitro preclinical research needs.
Why Choose TME Scientific?
1.Advanced In Vitro Models
We provide physiologically relevant models that deliver accurate, predictive data for drug discovery.
2.Comprehensive Service Portfolio
We offer a full range of in vitro preclinical services, including cell-based assays, toxicity testing, mechanism-of-action studies, and custom model developmentโsupporting your research from early discovery to IND-enabling studies.
3.Scientific Expertise
Our team of experienced scientists ensures high-quality, reproducible results using the latest techniques.
4.Tailored Solutions
We offer customized in vitro services to meet your unique research needs.
5.Efficiency & Speed
With streamlined workflows, we deliver reliable data quickly, accelerating your project timelines.
6.Collaborative Partnership
We prioritize transparent communication and offer continuous support throughout your project.
Partner with TME Scientific for reliable, high-quality in vitro preclinical services that drive your research forward.
Key Functional Assays to Assess Cancer Immunotherapies:
Take a moment to view our services
Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Assay โ
ADCC assays are designed to evaluate the ability of therapeutic antibodies to mediate immune effector cell killing of target cells via Fc receptor (FcฮณR) engagement.
Peptide-MHC binding assays for neoantigen validation โ
Peptide-MHC (major histocompatibility complex) binding assays are essential for neoantigen validation, as they determine whether a predicted neoantigen can effectively bind to MHC molecules and be presented to T cells for immune recognition. These assays help confirm neoantigen immunogenicity before advancing to clinical applications.
Cytokine Release Assay for Neoantigen Validation โ
The Cytokine Release Assay (CRA) is a critical assay for validating neoantigens, assessing their ability to activate T cells, and inducing immune responses. This assay helps determine whether a neoantigen can stimulate T cells to release cytokines, indicating a functional immune response.
MHC Tetramer Assay โ
The MHC tetramer assay is a powerful technique used to identify and quantify T cells that specifically recognize neoantigens presented by major histocompatibility complex (MHC) molecules. This assay is essential for validating the immunogenicity of neoantigens in cancer immunotherapy.
T-cell Cytotoxicity Assays (CD8+ T-cell killing assay) โ
T-cell cytotoxicity assays, particularly CD8+ T-cell killing assays, are essential tools for validating neoantigens by measuring the ability of these T cells to kill target cells expressing the specific neoantigen. These assays help assess the immunogenicity of neoantigens and their potential effectiveness in cancer immunotherapy.
Mixed Lymphocyte Reaction (MLR) Assay โ
The Mixed Lymphocyte Reaction (MLR) Assay is a functional in vitro assay used to evaluate T cell alloreactivity by measuring the proliferation of responder T cells upon exposure to allogeneic antigen-presenting cells (APCs). This assay is widely employed in transplantation immunology, immune tolerance studies, and immunotherapeutic development to assess the strength of alloimmune responses.
Immune Cell Activation Assay โ
The immune cell activation assay is used to evaluate the functional response of immune cells, such as T cells, B cells, or NK cells, upon exposure to stimuli. Activation is typically measured by monitoring changes in surface markers, cytokine secretion, or intracellular signaling molecules, providing insights into immune responses and the effects of immunomodulatory agents.
T-cell-based immunogenicity assay for evaluating human antigen-specific responses โ
Determining the antigen specificities of the endogenous T-cell repertoire is important for screening naturally occurring or therapy-induced T-cell immunity and may help identify novel targets for T-cell-based therapies. This assay enables the rapid, sensitive, and high-throughput expansion of antigen-specific T cells from human PBMCs using peptide stimulation and detecting antigen-specific effector cytokine formation.